Amid Wegovy's supply woes, Novo Nordisk sees surging demand for its original obesity drug Saxenda

After a contract manufacturing snafu in December, supply of Novo Nordisk’s GLP-1 med for obesity appears to be back on track in the U.S.—mostly.

Novo’s Wegovy manufacturing partner—which the Danish company previously confirmed to Fierce Pharma as Catalent—restarted production on the med in 2022’s second quarter. As a result, 1.7-mg and 2.4-mg doses of Wegovy are back on tap in the U.S. market, Novo said in a recent investor report. The company added that it expects all Wegovy dose strengths to be available in the U.S. later this year.